Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
26.51 ^USD	-1.49%		-0.56%	-8.40%

23/05	Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study	MT
23/05	Transcript : Supernus Pharmaceuticals, Inc. - Special Call

Supernus Pharmaceuticals, Inc. Announces Death of Board Member William Nuerge

January 13, 2018 at 01:45 am IST

Supernus Pharmaceuticals, Inc. announced that William Nuerge, a member of its Board of Directors, passed away on January 10, 2018.

Latest news about Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study	24/05	MT
Transcript : Supernus Pharmaceuticals, Inc. - Special Call	24/05
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M	09/05	MT
Supernus Pharmaceuticals, Inc. Seeks M&A	09/05	CI
Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	09/05
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024	09/05	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America	07/05	MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America	07/05	CI
Supernus Pharmaceuticals, Inc. Announces Retirement of John M. Siebert from the Board of Directors	25/04	CI
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	08/04	DJ
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	08/04	MT
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	08/04	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	08/04	RE
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	26/03	MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	22/03	MT
Transcript : Supernus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM	14/03
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating	28/02	MT
Transcript : Supernus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024	28/02
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023	28/02	CI
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	28/02	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	28/02	MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Supernus Pharmaceuticals, Inc. Announces Executive Changes	21/02	CI

Chart Supernus Pharmaceuticals, Inc.

Duration

Period

More charts

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Supernus Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.51 USD

Average target price

40.5 USD

Spread / Average Target

+52.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SUPERNUS PHARMACEUTICALS, INC.	-8.40%	1.46B
KYOWA KIRIN CO. LTD.	+17.03%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-24.00%	4.44B
YUHAN CORPORATION	+13.37%	4.24B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+31.17%	4.03B
INDIVIOR PLC	+7.51%	2.14B
BETTA PHARMACEUTICALS CO., LTD.	-34.04%	1.9B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.56%	1.94B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-47.93%	1.63B

Specialty & Advanced Pharmaceuticals